Inovio Pharmaceuticals Inc. (NASDAQ:INO) saw an upside of 3.82% to close Monday at $6.80 after adding $0.25 on the day. The 5-day average trading volume is 2,448,820 shares of the company’s common stock. It has gained $6.94 in the past week. An average of 3,501,235 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 4,589,340.
INO’s 1-month performance is -14.47% or -$1.15 on its low of $6.34 reached on 10/04/21. The company’s shares have touched a 52-week low of $5.81 and high of $19.00, with the stock’s rally to the 52-week high happening on 02/02/21. YTD, INO has lost -23.16% or -$2.05. However, the current price is down -64.21%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Aug 09, 64 days have gone by since the last insider trading activity for Inovio Pharmaceuticals Inc. (INO). Humeau Laurent (Chief Scientific Officer) most recently sold 10,317 shares at $9.15 per share on Aug 09. This transaction cost the insider $94,401. Chief Operating Officer, Shea Jacqueline Elizabeth, sold 38,535 shares at a price of $10.01 on Jun 09. Then, on Jun 09, Chief Scientific Officer Humeau Laurent sold 10,318 shares at a price of $9.07 per share. This transaction amounted to $93,584.
Inovio Pharmaceuticals Inc. (INO) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.24 for the sector.INO stock has a beta of 0.61. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 222.76 while the price-to-book (PB) in the most recent quarter is 2.80.
Inovio Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 10.50, with the current ratio over the same period at 10.50 meaning that INO stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.03, while the total debt to equity was 0.03The trailing 12-month EBITDA margin is -1698.16%. The firm’s gross profit as reported stood at $131.49 million against revenue of $7.41 million.
For the quarterly period ending June 29 this year, Inovio Pharmaceuticals Inc.’s cash and short-term investments amounted to $384.75 million against total debt of $33.8 million. Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected INO to announce -$0.25 per share in earnings in its latest quarter, but it posted -$0.39, representing a -56.00% surprise. EBITDA for the quarter stood at more than -$82.37 million. INO stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 83.29 million, with total debt at $33.8 million. Shareholders hold equity totaling $210.36 million
Let’s look briefly at Inovio Pharmaceuticals Inc. (INO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 40.74% to suggest the stock is trending Neutral, with historical volatility in this time period at 54.66%.
The stock’s 5-day moving average is $6.59, reflecting a +6.92% or $0.44 change from its current price. INO is currently trading -12.71% above its 20-day SMA, -0.73% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -19.05% and -32.47% respectively.
Stochastic %K and %D was 18.54% and 13.30% and the average true range (ATR) pointed at 0.36. The RSI (14) points at 39.28%, while the 14-day stochastic is at 27.06% with the period’s ATR at 0.38. The stock’s 9-day MACD Oscillator is pointing at -0.05 and -0.42 on the 14-day charts.
In the most recent analyst report for Inovio Pharmaceuticals Inc. (NASDAQ: INO), BofA Securities downgraded it to an Underperform rating. They previously had a Neutral rating on the stock.